Valion Bio (NASDAQ: VBIO) has announced that the Armed Forces Radiobiology Research Institute (AFRRI) will evaluate the therapeutic efficacy of Entolimod in a post-radiation treatment model designed to assess whether...
An October 28, 2026 fire at a South Carolina complex that once produced plutonium and tritium for nuclear weapons is a timely reminder of the importance of resilient emergency preparedness for potential radiological and...
Celularity (NASDAQ: CELU) and Vesalius Longevity Labs (CSE: VLAB) have announced an exclusive manufacturing agreement to establish a dedicated, first-of-its-kind, U.S. final stage API manufacturing and supply platform...
Azitra (NYSE American: AZTR) has announced amendments to its ongoing Phase 1/2 clinical trial of ATR04-484 that significantly expand patient eligibility to include individuals with rash associated with KRAS and MEK...
Valion Bio (NASDAQ: VBIO) has announced final data from a safety study funded by the National Institute of Allergy and Infectious Diseases (NIAID)/Radiation and Nuclear Countermeasures Program (RNCP) that evaluated its...
FireFly Neuroscience (NASDAQ: AIFF) has provided an update on its non-invasive brain-computer interface (BCI) strategy, highlighting the role of its commercially available Versus platform in pursuing the human...
Clearmind Medicine (NASDAQ: CMND) announced the completion of patient recruitment for the first segment of Part B of its ongoing Phase 1/2a clinical trial evaluating CMND-100 in patients with moderate-to-severe alcohol...
IRLAB Therapeutics (STO: IRLAB-A; FRA: 6IRA) has announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance (NOA) for a patent application covering IRL1117, a preclinical drug candidate...
Atrium Therapeutics (NASDAQ: RNA) has announced that the first patient has been dosed in its Phase 1/2 Corventis clinical trial evaluating ATR 1072, its lead investigational therapy for the potential treatment of PRKAG2...
Aclaris Therapeutics (NASDAQ: ACRS) has announced positive primary analysis results from the Phase 1b proof-of-concept (POC) trials of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 in atopic dermatitis and asthma...